0001193125-20-267232.txt : 20201009 0001193125-20-267232.hdr.sgml : 20201009 20201009162302 ACCESSION NUMBER: 0001193125-20-267232 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20201006 ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201009 DATE AS OF CHANGE: 20201009 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NN INC CENTRAL INDEX KEY: 0000918541 STANDARD INDUSTRIAL CLASSIFICATION: BALL & ROLLER BEARINGS [3562] IRS NUMBER: 621096725 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-39268 FILM NUMBER: 201233418 BUSINESS ADDRESS: STREET 1: 207 MOCKINGBIRD LANE CITY: JOHNSON CITY STATE: TN ZIP: 37604 BUSINESS PHONE: 423-434-8300 MAIL ADDRESS: STREET 1: 207 MOCKINGBIRD LANE CITY: JOHNSON CITY STATE: TN ZIP: 37604 FORMER COMPANY: FORMER CONFORMED NAME: NN BALL & ROLLER INC DATE OF NAME CHANGE: 19940203 8-K/A 1 d948551d8ka.htm FORM 8-K/A Form 8-K/A
NN INC true 0000918541 0000918541 2020-10-06 2020-10-06

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K/A

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 9, 2020 (October 6, 2020)

 

 

 

LOGO

NN, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   000-23486   62-1096725

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

6210 Ardrey Kell Road

Charlotte, North Carolina

   28277
(Address of principal executive offices)   (Zip Code)

(980) 264-4300

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

symbol

  

Name of each exchange

on which registered

Common Stock, par value $0.01   NNBR   The Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act:

None

(Title of class)

 

 

Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d- 2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company.  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Explanatory Note

This Amendment corrects certain typographical errors as well as errors in the calculation of certain Life Sciences Business Adjustments appearing in the unaudited pro forma condensed consolidated balance sheet of NN, Inc. (“NN”) as of June 30, 2020 and the unaudited pro forma condensed consolidated statements of operations of NN for the years ended December 31, 2017, December 31, 2018 and December 31, 2019 and the six months ended June 30, 2020, which were filed as Exhibit 99.2 to the Form 8-K filed with the Securities and Exchange Commission on October 8, 2020.

 

ITEM 9.01.

FINANCIAL STATEMENTS AND EXHIBITS.

(b)    Pro Forma Financial Information

NN’s unaudited pro forma condensed consolidated balance sheet as of June 30, 2020, and the unaudited pro forma condensed consolidated statements of operations for the years ended December 31, 2017, December 31, 2018 and December 31, 2019 and the six months ended June 30, 2020, and the notes related thereto, which have been updated to correct the errors noted above, are filed as Exhibit 99.1 and are hereby incorporated herein by reference.

(d) Exhibits

 

Exhibit
No.

   

Description

99.1    Unaudited pro forma condensed consolidated balance sheet of NN, Inc. as of June 30, 2020, and the unaudited pro forma condensed consolidated statements of operations for the years ended December 31, 2017, December 31, 2018 and December 31, 2019 and the six months ended June 30, 2020, and the notes related thereto (Updated)
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 9, 2020

 

NN, INC.
By:  

/s/ Matthew S. Heiter

Name:   Matthew S. Heiter
Title:   Senior Vice President, General Counsel
 EX-99.1 2 d948551dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION

On October 6, 2020, NN, Inc. (the “Company”) completed the sale of its life sciences business (the “Life Sciences Business”) to ASP Navigate Acquisition Corp. for total cash consideration of approximately $757.2 million. An additional earnout payment of up to $70 million may be payable to the Company during the year ending December 31, 2023, if certain performance measures are achieved by the Life Sciences Business through December 31, 2022.

The unaudited pro forma condensed consolidated balance sheet and the unaudited pro forma condensed consolidated statements of operations are derived from, and should be read in conjunction with, the historical financial statements and notes thereto of the Company, as presented in its Annual Report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission (“SEC”) on March 16, 2020, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, filed with the SEC on August 7, 2020.

The unaudited pro forma condensed consolidated financial statements have been prepared giving effect to the sale of the Company’s Life Sciences Business (the “Transaction”) as if the Transaction had occurred on June 30, 2020, for the unaudited pro forma condensed consolidated balance sheet and on January 1, 2017, for the unaudited pro forma condensed consolidated statements of operations. The unaudited pro forma condensed consolidated financial statements have been prepared giving effect to the required use of proceeds to prepay a portion of the Company’s credit facilities with all of the net proceeds from the Transaction as if the prepayment of credit facilities had occurred on June 30, 2020, for the unaudited pro forma condensed consolidated balance sheet and on January 1, 2017, for the unaudited pro forma condensed consolidated statements of operations.

The unaudited pro forma condensed consolidated financial statements are prepared in accordance with Article 11 of Regulation S-X. The pro forma adjustments are described in the accompanying notes and are based upon information and assumptions available at the time of the filing of this Current Report on Form 8-K.

The unaudited pro forma condensed financial statements do not purport to represent and are not necessarily indicative of what the Company’s actual financial position and results of operations would have been had the transaction occurred on the dates indicated. In addition, these unaudited pro forma condensed consolidated financial statements should not be considered to be indicative of the Company’s future financial performance.

The unaudited pro forma condensed consolidated financial information includes information, statements, and assumptions that are or may be considered “forward-looking” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally may be identified by the use of words such as “may,” “should,” “will,” “expect,” “anticipate,” “continue,” “estimate,” “project,” “believe,” “plan” or similar expressions. Statements that describe objectives, plans, or goals also are forward-looking statements. These forward-looking statements involve risks and uncertainties, and actual results may differ materially from those contemplated by the forward-looking statements due to, among other, the risks and uncertainties described under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. For any forward-looking statements contained herein, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and the Company undertakes no obligation to update publicly or revise any forward-looking statements in light of the new information or future events, except as required by law.

 

1

Unaudited Pro Forma Condensed Consolidated Balance Sheet

As of June 30, 2020

 

(in thousands)    Consolidated
Historical
NN, Inc.		      Life
Sciences
Business
Adjustments		     Other
Pro Forma
Adjustments		     Notes     Pro
Forma		  

Assets

            

Current assets:

            

Cash and cash equivalents

    $ 82,695      $ (12,158 )    $ 14,289       (h )    $ 84,826  

Accounts receivable, net

      105,661        (37,370 )      —           68,291  

Inventories

      121,031        (51,950 )      —           69,081  

Income tax receivable

      17,458        —         —           17,458  

Other current assets

      15,477        (4,087 )      —           11,390  
  

 

 

     

 

 

    

 

 

      

 

 

  

Total current assets

      342,322        (105,565 )      14,289         251,046  

Property, plant and equipment, net

      344,073        (116,050 )      —           228,023  

Operating lease right-of-use assets

      77,121        (24,825 )      —           52,296  

Goodwill

      196,467        (196,467 )      —           —    

Intangible assets, net

      306,577        (196,338 )      —           110,239  

Investment in joint venture

      22,104        —         —           22,104  

Other non-current assets

      7,350        (290 )      —           7,060  
  

 

 

     

 

 

    

 

 

      

 

 

  

Total assets

    $ 1,296,014      $ (639,535 )    $ 14,289       $ 670,768  
  

 

 

     

 

 

    

 

 

      

 

 

  

Liabilities, Preferred Stock, and Stockholders’ Equity

            

Current liabilities:

            

Accounts payable

    $ 43,751      $ (12,010 )    $ —         $ 31,741  

Accrued salaries, wages and benefits

      33,335        (15,925 )      —           17,410  

Income tax payable

      867        (267 )      —           600  

Current maturities of long-term debt

      20,567        (219 )      —           20,348  

Current portion of operating lease liabilities

      7,068        (2,618 )      —           4,450  

Other current liabilities

      32,266        (5,961 )      —           26,305  
  

 

 

     

 

 

    

 

 

      

 

 

  

Total current liabilities

      137,854        (37,000 )      —           100,854  

Deferred tax liabilities

      73,691        —         (56,821 )      (b )      16,870  

Long-term debt, net of current portion

      816,956        (884 )      (687,493 )      (a )      128,579  

Operating lease liabilities, net of current portion

      79,712        (22,912 )      —           56,800  

Other non-current liabilities

      31,195        (4,983 )      —           26,212  
  

 

 

     

 

 

    

 

 

      

 

 

  

Total liabilities

      1,139,408        (65,779 )      (744,314 )        329,315  

Series B convertible preferred stock

      98,707        —         —           98,707  

Total stockholders’ equity

      57,899        (573,756 )      758,603       (d )      242,746  
  

 

 

     

 

 

    

 

 

      

 

 

  

Total liabilities, preferred stock, and stockholders’ equity

    $ 1,296,014      $ (639,535 )    $ 14,289       $ 670,768  
  

 

 

     

 

 

    

 

 

      

 

 

  

See accompanying Notes to Unaudited Pro Forma Condensed Consolidated Financial Information.

 

2

Unaudited Pro Forma Condensed Consolidated Statement of Operations

For the Six Months Ended June 30, 2020

 

(in thousands, except per share data)    Consolidated
Historical
NN, Inc.		     Life Sciences
Business
Adjustments		     Other
Pro Forma
Adjustments		     Notes     Pro Forma  

Net sales

    $ 350,165       (156,447 )      —         $ 193,718  

Cost of sales (exclusive of depreciation and amortization shown separately below)

      267,630       (109,121 )      —           158,509  

Selling, general and administrative expense

      45,815       (14,024 )      (1,358 )      (c )      30,433  

Depreciation and amortization

      46,385       (23,701 )      —           22,684  

Goodwill impairment

      239,699       (146,757 )      —           92,942  

Other operating expense, net

      4,174       3       —           4,177  
  

 

 

    

 

 

    

 

 

      

 

 

  

Income (loss) from operations

      (253,538 )      137,153       1,358         (115,027 ) 

Interest expense

      35,773       345       (25,192 )      (e )      10,926  

Other expense, net

      239       259       —           498  
  

 

 

    

 

 

    

 

 

      

 

 

  

Income (loss) before benefit for income taxes

      (289,550 )      136,549       26,550         (126,451 ) 

Benefit (provision) for income taxes

      18,955       6,363       (5,575 )      (f )      19,743  

Share of net income from joint venture

      656       —         —           656  
  

 

 

    

 

 

    

 

 

      

 

 

  

Loss from continuing operations

    $  (269,939 )    $ 142,912     $ 20,975       $  (106,052 ) 
  

 

 

    

 

 

    

 

 

      

 

 

  

Basic net loss per common share:

           

Loss from continuing operations per common share

    $ (6.55 )          $ (2.66 ) 

Weighted average shares outstanding

      42,154             42,154  

Diluted net loss per common share:

           

Loss from continuing operations per common share

    $ (6.55 )          $ (2.66 ) 

Weighted average shares outstanding

      42,154             42,154  

See accompanying Notes to Unaudited Pro Forma Condensed Consolidated Financial Information.

 

3

Unaudited Pro Forma Condensed Consolidated Statement of Operations

For the Year Ended December 31, 2019

 

(in thousands, except per share data)    Consolidated
Historical
NN, Inc.		     Life Sciences
Business
Adjustments		     Other
Pro Forma
Adjustments		     Notes     Pro
Forma		  

Net sales

    $ 847,451       (359,732 )      —           $ 487,719  

Cost of sales (exclusive of depreciation and amortization shown separately below)

      641,639       (250,952 )      —           390,687  

Selling, general and administrative expense

      103,223       (34,330 )      —           68,893  

Depreciation and amortization

      91,846       (46,950 )      —           44,896  

Restructuring and integration expense, net

      (12 )      —         —           (12 ) 

Other operating expense (income), net

      866       (20 )      —           846  
  

 

 

    

 

 

    

 

 

      

 

 

  

Income (loss) from operations

      9,889       (27,480 )      —           (17,591 ) 

Interest expense

      57,155       498       (46,935 )      (e )      10,718  

Loss on extinguishment of debt and write-off of debt issuance costs

      3,293       —         (2,741 )      (g )      552  

Other expense (income), net

      1,140       (178 )      —           962  
  

 

 

    

 

 

    

 

 

      

 

 

  

Loss before benefit for income taxes

      (51,699 )      (27,800 )      49,676         (29,823 ) 

Benefit (provision) for income taxes

      3,277       7,728       (10,432 )      (f )      573  

Share of net income from joint venture

      1,681       —         —           1,681  
  

 

 

    

 

 

    

 

 

      

 

 

  

Loss from continuing operations

    $ (46,741 )    $ (20,072 )    $ 39,244       $ (27,569 ) 
  

 

 

    

 

 

    

 

 

      

 

 

  

Basic net loss per common share:

           

Loss from continuing operations per common share

    $ (1.13 )          $ (0.67 ) 

Weighted average shares outstanding

      42,030             42,030  

Diluted net loss per common share:

           

Loss from continuing operations per common share

    $ (1.13 )          $ (0.67 ) 

Weighted average shares outstanding

      42,030             42,030  

See accompanying Notes to Unaudited Pro Forma Condensed Consolidated Financial Information.

 

4

Unaudited Pro Forma Condensed Consolidated Statement of Operations

For the Year Ended December 31, 2018

 

(in thousands, except per share data)    Consolidated
Historical
NN, Inc.		     Life Sciences
Business
Adjustments		     Other
Pro Forma
Adjustments		     Notes     Pro Forma  

Net sales

    $ 770,657       (248,173 )      —         $ 522,484  

Cost of sales (exclusive of depreciation and amortization shown separately below)

      589,181       (177,497 )      —           411,684  

Selling, general and administrative expense

      93,583       (20,927 )      —           72,656  

Acquisition related costs excluded from selling, general and administrative expense

      5,871       (5,763 )      —           108  

Depreciation and amortization

      71,128       (28,102 )      —           43,026  

Goodwill impairment

      182,542       —         —           182,542  

Restructuring and integration expense, net

      2,127       (1,438 )      —           689  

Other operating expense, net

      6,089       737       —           6,826  
  

 

 

    

 

 

    

 

 

      

 

 

  

Loss from operations

      (179,864 )      (15,183 )      —           (195,047 ) 

Interest expense

      61,243       49       (52,671 )      (e)       8,621  

Loss on extinguishment of debt and write-off of debt issuance costs

      19,562       —         (19,562 )      (g)       —    

Other expense (income), net

      1,341       675       —           2,016  
  

 

 

    

 

 

    

 

 

      

 

 

  

Loss before benefit for income taxes

      (262,010 )      (15,907 )      72,233         (205,684 ) 

Benefit (provision) for income taxes

      13,413       3,802       (15,169 )      (f)       2,046  

Share of net loss from joint venture

      (14,390 )      —         —           (14,390 ) 
  

 

 

    

 

 

    

 

 

      

 

 

  

Loss from continuing operations

    $ (262,987 )    $ (12,105 )    $ 57,064       $ (218,028 ) 
  

 

 

    

 

 

    

 

 

      

 

 

  

Basic net loss per common share:

           

Loss from continuing operations per common share

    $ (8.30 )          $ (6.88 ) 

Weighted average shares outstanding

      31,678             31,678  

Diluted net loss per common share:

           

Loss from continuing operations per common share

    $ (8.30 )          $ (6.88 ) 

Weighted average shares outstanding

      31,678             31,678  

See accompanying Notes to Unaudited Pro Forma Condensed Consolidated Financial Information.

 

5

Unaudited Pro Forma Condensed Consolidated Statement of Operations

For the Year Ended December 31, 2017

 

(in thousands, except per share data)    Consolidated
Historical
NN, Inc.		     Life Sciences
Business
Adjustments		     Other
Pro Forma
Adjustments		     Notes     Pro
Forma		  

Net sales

    $ 619,793       (98,329 )      —         $ 521,464  

Cost of sales (exclusive of depreciation and amortization shown separately below)

      460,414       (64,949 )      —           395,465  

Selling, general and administrative expense

      74,112       (8,504 )      —           65,608  

Acquisition related costs excluded from selling, general and administrative expense

      344       —         —           344  

Depreciation and amortization

      52,406       (12,091 )      —           40,315  

Restructuring and integration expense, net

      386       —         —           386  

Other operating expense, net

      351       —         —           351  
  

 

 

    

 

 

    

 

 

      

 

 

  

Income (loss) from operations

      31,780       (12,785 )      —           18,995  

Interest expense

      52,085       52       (24,737 )      (e )      27,400  

Loss on extinguishment of debt and write-off of debt issuance costs

      42,087       —         (36,460 )      (g )      5,627  

Derivative gain on change in interest rate swap fair value

      (101 )      —         —           (101 ) 

Other expense (income), net

      (2,084 )      —         —           (2,084 ) 
  

 

 

    

 

 

    

 

 

      

 

 

  

Loss before benefit for income taxes

      (60,207 )      (12,837 )      61,197         (11,847 ) 

Benefit (provision) for income taxes

      79,545       (8,013 )      (21,419 )      (f )      50,113  

Share of net income from joint venture

      5,211       —         —           5,211  
  

 

 

    

 

 

    

 

 

      

 

 

  

Income from continuing operations

    $ 24,549     $ (20,850 )    $ 39,778       $ 43,477  
  

 

 

    

 

 

    

 

 

      

 

 

  

Basic net income per common share:

           

Income from continuing operations per common share

    $ 0.89           $ 1.58  

Weighted average shares outstanding

      27,433             27,433  

Diluted net income per share:

           

Income from continuing operations per common share

    $ 0.89           $ 1.58  

Weighted average shares outstanding

      27,755             27,755  

See accompanying Notes to Unaudited Pro Forma Condensed Consolidated Financial Information.

 

6

NOTES TO UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION

(In thousands, except per share information)

Note 1. Basis of Presentation

The historical consolidated financial statements have been adjusted in the pro forma condensed consolidated financial statements to give effect to pro forma events that are (1) directly attributable to the Transaction, (2) factually supportable and (3) with respect to the pro forma condensed consolidated statements of operations, expected to have a continuing impact on the Company.

The pro forma condensed consolidated financial statements do not necessarily reflect what the consolidated Company’s financial condition or results of operations would have been had the Transaction occurred on the dates indicated. They also may not be useful in predicting the future financial condition and results of operations of the Company. The actual financial position and results of operations may differ significantly from the pro forma amounts reflected herein due to a variety of factors.

The condensed consolidated pro forma financial information does not reflect the realization of any expected cost savings from the sale of the Life Sciences Business.

Note 2. Disposition of Life Sciences Business

The estimated net proceeds and gain on the sale of the Life Sciences Business, based on the historical book balances of the Life Sciences Business as of June 30, 2020, are as follows:

 

Proceeds from sale (1)

    $ 757,225  

Net assets sold as of June 30, 2020

      (573,756 ) 

Currency translation adjustment in accumulated other comprehensive income as of June 30, 2020

      (8,615 ) 

Transaction costs (2)

      (17,344 ) 
  

 

 

  

Estimated gain on sale (3)

    $ 157,510  
  

 

 

  

 

(1)

Only cash proceeds are considered in the estimated gain calculation. The potential earnout payment of up to $70 million will be recognized if the payment becomes probable.

(2)

Transaction costs include accounting, tax, valuation, consulting, legal and investment banking fees related to the sale of the Life Sciences Business, including approximately $1.4 million of Transaction costs expensed prior to June 30, 2020.

(3)

Using facts and circumstances available as of the date of this Current Report on Form 8-K, the Company expects no taxable gain on sale.

Note 3. Pro Forma Adjustments

The following are descriptions of the pro forma adjustments related to the Transaction:

 

  (a)

Reflects the allocation of net proceeds from the Transaction to prepay term loans under the Company’s credit facility. Collectively, the Company’s credit facility includes a senior secured term loan with an outstanding principal balance of $523.4 million as of June 30, 2020, an incremental term loan with an outstanding principal balance of $251.3 million as of June 30, 2020, and a senior secured revolver with an outstanding principal balance of $62.5 million as of June 30, 2020. The Company’s credit agreement, as amended on August 22, 2020, requires all net proceeds (as defined by the credit agreement) from the Transaction to be applied as a prepayment of the senior secured term loan and the incremental term loan. The pro forma adjustment to debt includes the following amounts:

 

7

     As of
June 30, 2020		  

Net proceeds used to pay down credit facilities

    $ (700,000 ) 

Accelerated amortization of debt issuance costs

      12,507  
  

 

 

  

Pro forma adjustment to debt

    $ (687,493 ) 
  

 

 

  

 

(b)

Represents the net deferred income tax liability related to the Life Sciences Business.

 

(c)

Reflects the removal of Transaction costs that were incurred prior to June 30, 2020, because they will not have a continuing impact on the Company.

 

(d)

The unaudited pro forma condensed consolidated statements of operations exclude the estimated gain resulting from the sale of the Life Sciences Business. This estimated gain will not have a continuing impact on the Company and is therefore reflected as a pro forma adjustment to stockholders’ equity in the unaudited pro forma condensed consolidated balance sheet. The pro forma adjustment to stockholders’ equity includes the following amounts:

 

     As of
June 30, 2020		  

Pro forma adjustment to debt

    $ 687,493  

Estimated cash on Life Sciences closing balance sheet

      14,289  

Deferred income taxes

      56,821  
  

 

 

  

Pro forma adjustment to stockholders’ equity

    $ 758,603  
  

 

 

  

 

(e)

Reflects the change in estimated interest expense and amortization of debt issuance costs incurred from the Company’s credit facility as a result of the requirement for the Company to use all net proceeds from the Transaction to prepay approximately $700.0 million on its term loans. The pro forma adjustment to interest expense is presented as if the Transaction and prepayment of debt had occurred on January 1, 2017. Amortization of debt issuance costs for the year ended December 31, 2017, includes $19.1 million of accelerated amortization on the assumed prepayment date of January 1, 2017. The pro forma adjustment to interest expense includes the following:

 

     Six Months Ended
June 30, 2020		      Year Ended December 31,  
     2019      2018      2017  

Interest on debt

    $ (22,745 )     $ (43,550 )     $ (49,049 )     $ (40,700 ) 

Amortization of debt issuance costs

      (2,447 )       (3,385 )       (3,622 )       15,963  
  

 

 

     

 

 

     

 

 

     

 

 

  

Pro forma adjustment to interest expense

    $ (25,192 )     $ (46,935 )     $ (52,671 )     $ (24,737 ) 
  

 

 

     

 

 

     

 

 

     

 

 

  

 

(f)

Represents the estimated income tax effect, using a federal statutory rate of 21% for 2020, 2019, and 2018, and 35% for 2017, related to the change in write-off of unamortized debt issuance costs and changes in interest expense. The effective tax rate of the Company after the Transaction may differ from what is presented in the unaudited pro forma condensed consolidated financial statements as a result of different tax jurisdictions.

 

(g)

Represents the loss on extinguishment of debt and write-off of unamortized debt issuance costs related to debt modifications as if the proceeds of the Transaction had been used for the required prepayment of the Company’s term loans as of January 1, 2017.

 

(h)

Represents estimated cash on closing balance sheet that was factored into the calculation of proceeds from sale.

 

8

EX-101.SCH 3 nnbr-20201006.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 nnbr-20201006_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Amendment Description Amendment Description EX-101.PRE 5 nnbr-20201006_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g948551g1008224320194.jpg GRAPHIC begin 644 g948551g1008224320194.jpg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end XML 7 d948551d8ka_htm.xml IDEA: XBRL DOCUMENT 0000918541 2020-10-06 2020-10-06 NN INC true 0000918541 8-K/A 2020-10-06 DE 000-23486 62-1096725 6210 Ardrey Kell Road Charlotte NC 28277 (980) 264-4300 Common Stock, par value $0.01 NNBR NASDAQ false false false false false This Amendment corrects certain typographical errors as well as errors in the calculation of certain Life Sciences Business Adjustments appearing in the unaudited pro forma condensed consolidated balance sheet of NN, Inc. (“NN”) as of June 30, 2020 and the unaudited pro forma condensed consolidated statements of operations of NN for the years ended December 31, 2017, December 31, 2018 and December 31, 2019 and the six months ended June 30, 2020, which were filed as Exhibit 99.2 to the Form 8-K filed with the Securities and Exchange Commission on October 8, 2020. XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information
Oct. 06, 2020
Cover [Abstract]  
Entity Registrant Name NN INC
Amendment Flag true
Entity Central Index Key 0000918541
Document Type 8-K/A
Document Period End Date Oct. 06, 2020
Entity Incorporation State Country Code DE
Entity File Number 000-23486
Entity Tax Identification Number 62-1096725
Entity Address, Address Line One 6210 Ardrey Kell Road
Entity Address, City or Town Charlotte
Entity Address, State or Province NC
Entity Address, Postal Zip Code 28277
City Area Code (980)
Local Phone Number 264-4300
Security 12b Title Common Stock, par value $0.01
Trading Symbol NNBR
Security Exchange Name NASDAQ
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Description This Amendment corrects certain typographical errors as well as errors in the calculation of certain Life Sciences Business Adjustments appearing in the unaudited pro forma condensed consolidated balance sheet of NN, Inc. (“NN”) as of June 30, 2020 and the unaudited pro forma condensed consolidated statements of operations of NN for the years ended December 31, 2017, December 31, 2018 and December 31, 2019 and the six months ended June 30, 2020, which were filed as Exhibit 99.2 to the Form 8-K filed with the Securities and Exchange Commission on October 8, 2020.
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( .""25$'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #@@DE1@\)_CNT K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)VUAP=#M1?&D(+B@> N3V=U@TX1DI-VWMXV[740?P&-F_GSS M#4R+0:&/]!Q]H,B6TLWD^B$I#%MQ9 X*(.&1G$[EG!CFYMY'IWE^Q@,$C1_Z M0%!+N0%'K(UF#0NP""M1=*U!A9$T^WC&&USQX3/V&680J"=' R>HR@I$MTP, MIZEOX0I88$S1I>\"F968JW]BWI\R>L6=DBL M!Z3Y5[**3X&VXC+YM;F[WSV(KI:U+"I9R-M=M5%UHZ1\7UQ_^%V%G3=V;_^Q M\46P:^'7771?4$L#!!0 ( .""25&97)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ MX())40]4ND%A!0 _A( !@ !X;"]W;W)K&E37)'2+JQMI2%;+W;;C\(6V"MMN5)ID6F."[:0OOI(C_35R\56R*\J8DS#+HE3==F*M,[>=KLJB%A"54=D M+,5?UD(F5..KW'15)AD-;:$D[A+/&W03RM/6U85-6\BK"Y'KF*=L(4'E24+E M_IK%8GO9\EN/"7=\$VF3T+VZR.B&+9G^(UM(?.N6*B%/6*JX2$&R]65KXK^] M)N>F@,WQ)V=;]>093%-60GPU+[/PLN49(A:S0!L)BE\/;,KBV"@AQW\'T599 MIRGX]/E1_;UM/#9F116;BO@+#W5TV1JU(&1KFL?Z3FQ_98<&6[0$4\*C(X5((<"Q'(7%5G*&ZKIU8446Y F-ZJ9 M!]M46QKA>&JBLM02?^583E_=B"#'3M9 TQ!N4\WU'F9I$6WLM8NNQDI,UFYP M$+PN!,D1P<^![H W: /QB/>\>!?92D!2 A*KUSNB-Q4/3,+?DY72$D/XCT.R M5TKVK&3_B.2AF7=LPXTH-GY.$U;75+?.? ZS^=0!U"^!^DZA"48@M%%X']-- M'8B[O)8Y-QXSF.?) MBLDZ$+<&CJWZL\SSN%Z)[N8!9B2/F:!T6G'>=KD!R0,]\;#X;D MW$7XQ)7]4P@G82B94NW'!_B(^>!S6AO*!LD!\3V82-39XZ2.8[@3-'3!5@[M MD^^"G9HW(>%>;.L7$+?<-*(R%OKES'H.5WF]?Y+9EW#%M$"ZA10// WJN[+! M^%VF[U>N[[MM^R7:0BB-OOL7SXY.UP9%,B+#H8NM6@I\MX/;&$YPGW<CSRWKA0*OOWW0;^4038*XM(I"[_:! A@_Y9O^>YW-:O5@+?;>!+%N32=)!/ M5G#/=5S?06Z1J4@2:],B^-J&C$IXH''.X">OX[F63;]:%7RW>]]+&O)T \M] MLA)Q+:);8#Z_OG.15"N [[;OLL-N=T%$TPT[NN-J$)I/EC>3WUW;RFH1(&[' M_H) FJ5@XI"GAP5 U3$U"*UIK%Q>12K7)VZ+7HJ8!UR;F'U"EY*K$[<#?D,V4RI&L$= M MVPA8>3LYR=MO$R8W)IZ_H(*.#'-&T]H==8-@(UIE[<3MS-5IXX:I0/+LV$&O M0><^X@HJ,=Q[2CQJ*PB8U)2GH/>9V$B:1=SX-Y-22 54P=9L/O#[D&)R1@PP M3Y#'Q2Y,K$N1CWS-8!EP$V@%U[E""-P'3<)_\6QLZD7)+&-4FDX^2.4IS4.N M60B9%&#/LDB' R-5F(9/"N=92$V&%8TI*D-Q X+USN=MLX_NP.N??QP1XKV; MS^V#_^Z-8<85$QHH-NRJJ-V6MXAX;A9V$ M$GC.8#C,<>&#GF_J]8?M;Y)&%N5EZK@$5'P'N-[HZ%'S63O:L,4P11@;G%AK MW*F'IK6WNXBON(;QN$- "ZMC[D( SU2'7%N.H]JD'RR>8Y3L5<*CT9M9RI6] MQ,$/'GV$P1L5U7;J!G3WR6V&N1GZ1,T44A"S-8Y#KS/$82F+RY;B18O,7G"L M<-,H$OL8,8H^8#+@[VLA]..+N3,IK[RN_@=02P,$% @ X())48.II0/4 M 0 ,@8 T !X;"]S='EL97,N>&ULU57;BM1 $/V5IC_ GD1V04D"*BP( M*@L[#[YVDDK2T#<[E3'9K[<[G=NX#*@/HB^3.J>J3YV^3M;C).&I T R*JG[ MG':(]BUC?=6!XOTK8T'[3&. M5&;0F-,39476&+TSKVDD?"E70"Y.;E,;5X+8V"5VI(I/0!#M.M%WXHK$L)!&-\D$M M><GSVL(Y; RU8@Y5/8PJ_-E?;8D+@7'^NP#21,=0V]H26,,A$$_:-:U#[( MWOV1++'B8O#]X&>C9_QM, B/#AHQSGALMOZWU)/;ZMQ:.;V3HM4*XMQ_N6&1 M\74PQ6]NJ ;2\)#F-,OX7V5NP=2#D*BT OJ1%V#?G%/O3SR MTC_@5_J^OH:&#Q+/6S*G>_P9:C&H-UO58UB7I6J//X7W*+F?&^[_$L4/4$L# M!!0 ( .""25&7BKL

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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d948551d8ka.htm d948551dex991.htm nnbr-20201006.xsd nnbr-20201006_lab.xml nnbr-20201006_pre.xml g948551g1008224320194.jpg http://xbrl.sec.gov/dei/2019-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d948551d8ka.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d948551d8ka.htm" ] }, "labelLink": { "local": [ "nnbr-20201006_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "nnbr-20201006_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "nnbr-20201006.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "nnbr", "nsuri": "http://www.nninc.com/20201006", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d948551d8ka.htm", "contextRef": "duration_2020-10-06_to_2020-10-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d948551d8ka.htm", "contextRef": "duration_2020-10-06_to_2020-10-06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description", "terseLabel": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.nninc.com//20201006/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 16 0001193125-20-267232-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-267232-xbrl.zip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end